natgillin/translations-raw huggingface dataset:
Ciclesonide exhibits low binding affinity to the glucocorticoid-receptor. 
Ciklesonid kaže nizko afiniteto za vezavo na glukokortikoidne receptorje.
Ciclesonide is a glucocorticoid used to treat obstructive airway disease. 
Ciklesonid je glukokortikoid, ki se uporablja za zdravljenje obstruktivne bolezni dihal.
In four clinical trials, ciclesonide has been shown to reduce airway hyperresponsivenes to adenosine monophosphate in hyperreactive patients with maximal effect observed at the dose of 640 micrograms. 
Štiri klinična preskušanja so pokazala, da ciklesonid zmanjša pretirano odzivnost dihal na adenozin monofosfat pri hiperreaktivnih bolnikih z maksimalnim učinkom opaženim pri odmerku 640 mikrogramov.
Regular check-ups with your doctor will ensure that you are taking the right dose of Alvesco for you. 
Zdravnik vam bo z rednimi pregledi zagotovil ustrezen odmerek zdravila Alvesco.
AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE LABELLING 
DOPOLNILA, KI NAJ SE VKLJUČIJO V ODGOVARJAJOČA POGLAVJA OZNAČEVANJA
The data presented in the responses only reiterated the fact that there is no effective dose ranging data comparing 160, 320 and 640µg/d. 
Podatki, ki jih je imetnik dovoljenja za promet z zdravilom predstavil v odgovoru, so zgolj ponovno potrdili, da podatki za opredelitev učinkovitega odmerka, ki bi primerjali odmerke 160, 320 in 640 µg/dan, niso na voljo.
- The MAH has proposed an adequate study which would resolve the outstanding question on the long term use of 320 µg and 640 µg daily. 
- imetnik dovoljenja za promet z zdravilom je predlagal ustrezno študijo, s katero bi bilo mogoče podati odgovor na nerešeno vprašanje o dolgoročni uporabi odmerka 320 µg oz. 640 µg na dan;
At the end of the 12 week study period, the results showed a statistically significant difference between the doses of 160 micrograms and 640 micrograms/day ciclesonide with regard to the occurrence of an exacerbation after the first day of the study: 43 patients/339 (= 12.7%) in the 160 micrograms/day group and 23 patients/341 (6.7%) in the 640 micrograms/day group (Hazard ratio=0.526; p= 0.0134). 
Po koncu obdobja 12 tedenske raziskave so rezultati pokazali statistično pomembno razliko med odmerkoma 160 mikrogramov in 640 mikrogramov ciklesonida dnevno glede na pojavnost poslabšanja po prvem dnevu raziskave: 43 bolnikov od 339 (12,7%) v skupini z dnevnim odmerkom 160 mikrogramov in 23 bolnikov od 341 (6,7%) v skupini z dnevnim odmerkom 640 mikrogramov (stopnja tveganja=0,526; p=0,0134).
In another trial, pretreatment with ciclesonide for seven days significantly attenuated the early and late phase reactions following inhaled allergen challenge. 
Neka druga raziskava je pokazala, da je predhodno sedemdnevno zdravljenje s ciklesonidom po poskusu inhalacije alergena znatno zmanjšalo zgodnjo in pozno fazo reakcij.
The inhaler is an aluminium canister containing 120 doses of either 40 µg, 80 µg or 160 µg ex actuator, corresponding to 50, 100, or 200 µg per puff ex valve. 
Inhalator je aluminijast vsebnik, ki vsebuje 120 odmerkov po 40 µg, 80 µg ali 160 µg dostavljenega odmerka, kar ustreza 50, 100 ali 200 µg na vpih merjenega odmerka.
In a clinical trial involving 164 adult male and female asthmatic patients, ciclesonide was given at doses of 320 micrograms or 640 micrograms/day over 12 weeks. 
V kliničnem preskušanju, v katerem je sodelovalo 164 odraslih moških in žensk z astmo, so ciklesonid dajali v odmerkih 320 mikrogramov ali 640 mikrogramov na dan 12 tednov.
The CHMP referred to the NfG on the Clinical Investigation of Medicinal Products in the Treatment of Asthma CPMP/EWP/2922/01, and was of the opinion that the MAH had not adequately justified the inclusion of the 320µg/d and 640µg/d ciclesonide. 
CHMP je opozoril na navodilo za klinično raziskovanje zdravil za zdravljenje astme (Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Asthma) CPMP/EWP/2922/01 ter izrazil mnenje, da imetnik dovoljenja za promet z zdravilom ni ustrezno utemeljil vključitve odmerkov 320 µg in 640 µg ciklesonida dnevno.
United Kingdom Nycomed GmbH Byk-Gulden-Str. 2 
Velika Britanija Nycomed GmbH Byk-Gulden-Str. 2
Additionally, the MAH agreed to amend the wording for Section 5.1 in order to include more detail on Study M1 140, to indicate that there was a statistically significant difference between the doses of 160 micrograms/day and 640 micrograms/day ciclesonide with regards to the occurrence of an exacerbation after the first day of the study. 
Imetnik dovoljenja za promet z zdravilom se je strinjal z dopolnitvijo besedila za poglavje 5.1, in sicer, da se vključi več podrobnosti o študiji M1 140 in navede, da je bila prisotna statistično pomembna razlika med odmerkom 160 mikrogramov in 640 mikrogramov ciklesonida na dan glede na izbruh astme po prvem dnevu študije.
Additionally, no study submitted by the MAH showed a significant improvement in FEV1 above 160µg/d in asthmatics. 
Poleg tega nobena izmed študij, ki jih je predložil imetnik dovoljenja za promet z zdravilom, ni pokazala bistvenega izboljšanja forsiranega ekspiratornega volumna (FEV1) pri astmatikih pri odmerku nad 160 µg/dan.
The valid labelling is the final version achieved during the Coordination group procedure. 
Veljavno označevanje je končna različica pripravljena v skupini za koordiniranje.
Alvesco 40 Inhaler, 80 Inhaler and 160 Inhaler are products containing ciclesonide, delivered in a pressurized metered dose inhaler containing ethanolic hydrofluoroalkane-134A as propellant. 
Alvesco 40 v inhalatorju, 80 v inhalatorju in 160 v inhalatorju so zdravila, ki vsebujejo ciklesonid in so na voljo v odmernem inhalatorju pod tlakom, ki vsebuje potisni plin etanolni hidrofluoroalkan-134A.
Before you use Alvesco (This section contains important information for your safety) How to use Alvesco 
Kaj je zdravilo Alvesco in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Alvesco (v tem poglavju so pomembne informacije za vašo varnost)
- The proposed wording for Sections 3, 4 and 5 of the Package Leaflet at the end of the CMDh procedure have been amended accordingly. 
- predlagano besedilo za poglavja 3, 4 in 5 navodila za uporabo je bilo ob zaključku postopka v okviru CMDh ustrezno dopolnjeno;
- This medicine has been prescribed for you. 
- Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS 
DOPOLNILA, KI NAJ SE VKLJUČIJO V ODGOVARJAJOČA POGLAVJA POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA
The CHMP considered the MAH's response to support the additional changes to Section 4.2 of the SPC. 
CHMP je obravnaval odgovor imetnika dovoljenja za promet z zdravilom v podporo dodatnim spremembam poglavja 4.2 povzetka glavnih značilnosti zdravila.
- The applicant/MAH is requested to commit to obtaining scientific advice in relation to exploring a suitable study design, and execute such study (ies) to provide further information on the use of the higher dose of Alvesco in the control of severe asthma. 
- predlagatelj/imetnik dovoljenja za promet z zdravilom je pozvan, da pridobi znanstveni nasvet za določitev primerne oblike študije ter da izvede takšno študijo (ali več študij), ki bodo zagotovile nadaljnje informacije o uporabi večjega odmerka zdravila Alvesco za nadzor hude astme.
Read all of this leaflet carefully before you start using this medicine. 
Pred uporabo natančno preberite navodilo!
In a 12-week study of 680 severe asthmatics, previously treated with 500 - 1000 micrograms fluticasone propionate per day or equivalent, 87.3% and 93.3% of patients remained exacerbation-free during treatment with 160 or 640 micrograms of ciclesonide, respectively. 
V 12-tedenski raziskavi 680 hudih astmatikov, ki so bili predhodno zdravljeni s 500-1000 mikrogrami flutikazon-propionata na dan ali z enakovrednim odmerkom, je ob zdravljenju s 160 ali 640 mikrogrami ciklesonida ostalo brez poslabšanja bolezni 87,3% in 93,3% bolnikov.
The applicant/MAH is requested to commit to obtaining scientific advice in relation to exploring a suitable study design, and execute such study (ies) to provide further information on the use of the higher dose of Alvesco in the control of severe asthma. 
Predlagatelj/imetnik dovoljenja za promet z zdravilom je pozvan, da pridobi znanstven nasvet za določitev primerne oblike študije ter da izvede takšno študijo (ali več študij), ki bodo zagotovile nadaljnje informacije o uporabi večjega odmerka zdravila Alvesco za nadzor hude astme.
The Package Leaflet amendments include a note on increasing the dosage of Alvesco up to 640 micrograms/day, delivered as 320 micrograms twice daily, for a short period in patients who experience a worsening of their asthma symptoms. 
Spremembe navodil za uporabo vključujejo navodilo glede kratkoročnega povečanja odmerka zdravila Alvesco na 640 mikrogramov/dan v obliki dveh dnevnih odmerkov po 320 mikrogramov pri bolnikih, pri katerih je prišlo do poslabšanja simptomov astme.
The valid Summary of Product Characteristics is the final version achieved during the Coordination group procedure with the following amendments: 
Veljavni povzetek glavnih značilnosti zdravila je končna različica pripravljena v skupini za koordiniranje s sledečimi dopolnili:
The recommended dose of Alvesco is 160 micrograms once daily, which leads to asthma control in the majority of patients. 
Priporočeni odmerek zdravila Alvesco je 160 mikrogramov enkrat dnevno, kar omogoča nadzor astme pri večini bolnikov.
ANNEX II SCIENTIFIC CONCLUSIONS AND GROUNDS FOR AMENDMENT OF THE SUMMARY(IES) OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET PRESENTED BY THE EMEA 
DODATEK II ZNANSTVENI ZAKLJUČKI IN PODLAGA ZA DOPOLNILO POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA, OZNAČEVANJA IN NAVODILA ZA UPORABO, KI JIH JE PREDSTAVILA EVROPSKA AGENCIJA ZA ZDRAVILA
- The proposed wording for Section 4.2 of the SPC at the end of CMDh procedure has been amended to reflect that in severe asthmatics, a 12 week study has shown that a dose of 640µg/d (given 320µg/d twice daily) has demonstrated a reduction in the frequency of exacerbations but without an improvement in lung function. 
- predlagano besedilo poglavja 4.2 povzetka glavnih značilnosti zdravila je bilo ob zaključku postopka v okviru CMDh dopolnjeno tako, da odraža ugotovitev iz 12-tedenske študije, da je pri hudih astmatikih odmerek 640 µg/dan (v obliki dveh odmerkov po 320 µg na dan) vplival na zmanjšanje pogostosti izbruhov, vendar ni izboljšal funkcije pljuč;
The valid package leaflet is the final version achieved during the Coordination group procedure with the following amendments: 
Veljavno navodilo za uporabo je končna različica pripravljena v skupini za koordiniranje s sledečimi dopolnili:
A study powered to show a statistically significant difference between all doses, is considered to be the most adequate from a statistical and clinical point of view The trial proposed (referred to as Scenario B) should generate all the information needed by the applicant in order to submit a variation to Section 4.2 of the SPC which would include a recommendation to use higher doses of ciclesonide as proposed by the MAH. 
Predlagana študija (imenovana scenarij B) bo predvidoma zagotovila vse informacije, ki jih vlagatelj potrebuje za predložitev spremembe poglavja 4.2 povzetka glavnih značilnosti zdravila, ki bi naj vključevalo priporočilo za uporabo večjih odmerkov ciklesonida, v skladu s predlogom imetnika dovoljenja za promet z zdravilom.
• The recommended dose of Alvesco is 160 micrograms once daily, which leads to asthma control in the majority of patients. 
• Priporočen odmerek zdravila Alvesco je 160 mikrogramov enkrat dnevno, kar pri večini bolnikov vodi do obvladovanja astme.
However in severe asthmatics, a 12 week study has shown that a dose of 640 micrograms/day (given 320 micrograms twice daily) has demonstrated a reduction in the frequency of exacerbations but without an improvement in lung function (see section 5.1). 
Vendar je pri hudih astmatikih 12 tedenska študija pokazala, da je odmerek 640 mikrogramov/dan (odmerjen dvakrat dnevno po 320 mikrogramov) privedel do znižanja pogostnosti poslabšanj, toda brez izboljšanja pljučne funkcije (glejte poglavje 5.1).
The proposed wording of the Package Leaflet at the end of the CMDh was also modified to be in line with the amendments to the SPC. 
Predlagano besedilo navodila za uporabo je bilo ob zaključku postopka v okviru CMDh spremenjeno v skladu z dopolnitvami povzetka glavnih značilnosti zdravila.
HOW TO USE ALVESCO 
Kako uporabljati zdravilo Alvesco
Immediate or delayed hypersensitivity reactions such swelling of lips, tongue and throat (angioedema). 
Zelo redki neželeni učinki (pojavijo se pri manj kot enem od 10.000 bolnikov): Takojšnje ali zapoznele preobčutljivostne reakcije kot je otekanje ustnic, jezika in grla (angioedem).
GROUNDS FOR AMENDMENT OF THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 
PODLAGA ZA DOPOLNITEV POVZETKA GLAVNIH ZNAČILNOSTI ZDRAVILA, OZNAČEVANJA IN NAVODILA ZA UPORABO
However in severe asthmatics, a 12 week study has shown that a dose of 640µg/d (given 320µg/d twice daily) has demonstrated a reduction in the frequency of exacerbations but without an improvement in lung function (see section 5.1). 
Vendar pa je 12-tedenska študija pokazala, da je pri hudih astmatikih odmerek 640 µg/dan (v obliki dveh dnevnih odmerkov po 320 µg) privedel do zmanjšanja pogostosti izbruhov, vendar ni izboljšal funkcije pljuč (glejte poglavje 5.1).
ANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET 
DODATEK III DOPOLNILA K POVZETKU GLAVNIH ZNAČILNOSTI ZDRAVILA, OZNAČEVANJU IN NAVODILU ZA UPORABO
please tell your doctor or pharmacist. 
Če ste negotovi, se posvetujte z zdravnikom ali s farmacevtom.
HOW TO STORE ALVESCO 
Shranjevanje zdravila Alvesco
Treatment-related adverse events were seen in 3.8% and 5% of patients treated with 160 or 640 micrograms per day of ciclesonide respectively. 
Neželene učinke v povezavi z zdravljenjem so opazili pri 3,8% bolnikov, ki so bili zdravljeni s 160 mikrogrami ciklesonida na dan ter pri 5% bolnikov zdravljenih s 640 mikrogrami ciklesonida na dan. Raziskava, kjer bi primerjali dnevne odmerke 160 mikrogramov, 320 mikrogramov in 640 mikrogramov pri bolnikih s hudo astmo, ni bila izvedena.
Always use this medicine exactly as your doctor has told you. 
Pri uporabi tega zdravila natančno upoštevajte zdravnikova navodila.
AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE PACKAGE LEAFLET 
DOPOLNILA, KI NAJ SE VKLJUČIJO V ODGOVARJAJOČA POGLAVJA NAVODILA ZA UPORABO
Marketing Authorisation Holder 
Država članica Imetnik dovoljenja za promet z zdravilom
PACKAGE LEAFLET: INFORMATION FOR THE USER Alvesco 40, 80 and 160 micrograms pressurised inhalation, solution Ciclesonide 
Alvesco 40, 80 in 160 µg inhalacijska raztopina pod tlakom Ciklesonid
ANNEX 
DODATEK
The monitoring of NO2 formation 
• Nadzor nastajanja NO2
Educational material for Healthcare Professionals 
• Izobraževalni material za zdravstvene delavce.
The educational material should be a pocket size guide that includes information on the following key elements: 
Izobraževalni material naj bo vodič žepne velikosti, ki vključuje informacije o naslednjih ključnih elementih:
The monitoring of Methaemoglobin level 
• Nadzor ravni methemoglobina
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI MORAJO BITI IZVEDENI V DRŽAVAH ČLANICAH
The Marketing Authorisation Holder (MAH) should ensure that, at launch of the new indication, all Healthcare Professionals who are expected to use and/or prescribe INOmax as part of the treatment of peri- or post- operative pulmonary hypertension in adults and children in conjunction to heart surgery are provided with an Educational pack. 
• Imetnik dovoljenja za promet z zdravilom (MAH) mora zagotoviti, da ob uvedbi nove indikacije vsi zdravstveni delavci, za katere se pričakuje, da bodo uporabljali in/ali predpisovali zdravilo INOmax v okviru zdravljenja pred- ali pooperativne pljučne hipertenzije pri odraslih in otrocih, povezane s srčnim kirurškim posegom, dobijo gradivo za izobraževanje.
The risk of rebound effect and the precautions to take when discontinuing the treatment The risk of abrupt discontinuation of Inomax therapy in the event of critical failure of the delivery system and how to prevent it 
• Tveganje nenadne prekinitve zdravljenja z zdravilom INOmax v primeru kritične odpovedi sistema za dovajanje in kako to preprečiti
The potential risk of bleeding and haemostasis disorders The potential risks if used in combination with other vasodilators which act on cGMP or cAMP 
• Potencialna tveganja, če se uporablja v kombinaciji z drugimi vazodilatatorji, ki delujejo na cGMP ali cAMP.
The educational pack should contain the following: Summary of Product Characteristics and Patient Information Leaflet for INOmax 
Gradivo za izobraževanje naj vsebuje naslednje: • Povzetek glavnih značilnosti zdravila in navodila za uporabo zdravila INOmax
The Member States must ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented in their national territory: Prior to launch of the new indication of the product in the Member State, the national competent authority shall agree the content and format of the educational material with the Marketing Authorisation Holder 
• Pred uvedbo nove indikacije za zdravilo v državi članici naj imetnik dovoljenja promet z zdravilom pridobi soglasje o vsebini in obliki izobraževalnega materiala s pristojnim nacionalnim organom.
The Opinion was not properly reasoned. 
Mnenje ni bilo ustrezno utemeljeno.
The CHMP's conclusions were arbitrary. 
Sklepi CHMP so bili arbitrarni.
The Committee is therefore of the opinion that its 22 July 2010 opinion should be maintained. 
Odbor je tako menil, da je treba mnenje z dne 22. julija 2010 ohraniti.
Re-examination procedure 
Postopek ponovnega pregleda
The new formulation must be approved by the National Competent Authorities of the concerned Member States (see Annex IV). 
Novo formulacijo morajo odobriti pristojni nacionalni organi zadevnih držav članic (glejte Prilogo IV).
About 20% of the responders reported chronic pain (>6 months). 
Okoli 20 odstotkov odzivnih bolnikov je poročalo o kronični bolečini (>6 mesecev).
This aspect is outside the scope of this procedure and it does not provide any relevant information to the issue at stake. 
Ta vidik ne sodi v okvir tega postopka in ne ponuja nobenih pomembnih informacij glede obravnavanega vprašanja.
It is well known that food can have an effect on the pharmacokinetic parameters of medicinal products. 
Dobro znano je, da lahko hrana vpliva na farmakokinetične parametre zdravil.
In its assessment, the Committee took into consideration data submitted for the different timepoints. 
Odbor je pri ocenjevanju upošteval predložene podatke za različne časovne točke.
On 18 September 2009, the European Commission triggered a referral under Article 31 of Directive 2001/83/EC, as amended. 
Evropska komisija je 18. septembra 2009 sprožila napotitveni postopek v skladu s členom 31 Direktive 2001/83/ES, kakor je bila spremenjena.
The remaining systems were not significantly affected by alcohol. 
Na preostale sisteme alkohol ni pomembneje vplival.
Quality issues 
Vprašanja kakovosti
The question under discussion is, however, whether the magnitude of the interaction is such that it can be assumed to have clinical significance and represent a significant risk for the patient. 
Obravnavano vprašanje pa je, ali je obseg interakcij takšen, da bi lahko bil klinično pomemben in predstavljal pomembno tveganje za bolnika.
In particular, assumptions were made about the behaviour of some formulations based solely on the excipients; in this respect the CHMP did not take into account the evidence provided in the Oral Hearing on 23 June 2010 that such assumptions are flawed. 
Zlasti so bile oblikovane predpostavke o delovanju nekaterih formulacij, ki so bile utemeljene zgolj na pomožnih snoveh; pri tem CHMP ni upošteval dokazov, predloženih na ustni obravnavi dne 23. junija 2010, da so takšne predpostavke napačne.
However, a significant percentage of the patients with chronic pain who uses opioids still reports high alcohol intake (10.8%) and binge drinking at least once a month (22.3%), despite existing warnings. 
Kljub temu pa pomemben odstotek bolnikov s kronično bolečino, ki uporabljajo opioide, še vedno poroča o visokem vnosu alkohola (10,8 odstotka) in popivanju vsaj enkrat na mesec (22,3 odstotka) navkljub obstoječim opozorilom.
This product has never been marketed. 
To zdravilo ni bilo nikoli trženo.
This further illustrates the limitations of the data presented. 
To prav tako kaže na to, da so predstavljeni podatki omejeni.
Source; Brennan et al., Addiction 2005; 100 : 777-86 
Vir: Brennan et al., Addiction 2005; 100 : 777-86
Benefit-Risk balance 
Razmerje med koristmi in tveganji
Dissolution data was submitted for two different controlled release systems of hydromorphone, four different controlled release systems of oxycodone, and seven different controlled release systems containing morphine. 
Podatki o raztapljanju so bili predloženi za dva različna sistema z nadzorovanim sproščanjem hidromorfona, štiri različne sisteme z nadzorovanim sproščanjem oksikodona ter sedem različnih sistemov nadzorovanega sproščanja, ki so vsebovali morfin.
In the scientific literature, drinking alcohol is referred as a coping mechanism to deal with the stress associated with pain. 
V znanstveni literaturi se pitje alkohola obravnava kot mehanizem za spoprijemanje s stresom, povezanim z bolečino.
For most of the products assessed, only in vitro data was submitted. 
Za večino ocenjevanih zdravil so bili predloženi samo in vitro podatki.
In this study, subjects were interviewed about their number of alcohol consumptions of the last week and frequency of binge drinking in the last month (5292 responders). 
V tej študiji so preiskovance spraševali o količini porabljenega alkohola v preteklem tednu in pogostosti popivanja v preteklem mesecu (5292 odzivnih bolnikov).
Secondly, the CHMP's approach to alcohol interaction is inconsistent with its approach to food interactions. 
Drugič, pristop CHMP do interakcije z alkoholom ni skladen z njegovim pristopom do interakcije s hrano.
A significant effect was observed also in a hydromorphone once a day formulation which is not marketed in the EU. 
Pomemben vpliv so opazili tudi pri formulaciji hidromorfona za uporabo enkrat na dan, ki se v EU ne trži.
The effect of alcohol on the dissolution rate was mild in most cases, except for one morphine formulation (morphine once-daily capsules). 
Vpliv alkohola na stopnjo raztapljanja je bil v večini primerov blag, razen pri eni formulaciji morfina (kapsule morfina enkrat na dan).
Both problem drinkers and non-problem drinkers were included. 
Vključeni so bili tako problematični kot neproblematični pivci.
It is important to note in this regard that the effects of food related interactions are measured in vivo, and therefore the data on food effect reflects, as accurately as possible, the real extent of the interaction. 
V zvezi s tem je pomembno omeniti, da so interakcije, povezane s hrano, merjene in vivo, kar pomeni, da podatki o učinku hrane kar najbolj natančno odražajo resnični obseg interakcije.
This will be related to the specificities of each formulation, namely the physical characteristics of the excipients and the manufacturing process. 
Na to vplivajo predvsem posebnosti posameznih formulacij, in sicer fizikalne lastnosti pomožnih snovi in proizvodni postopek.